Theodore Abraham is a Cardiology physician affiliated with Bristol-Myers Squibb. OpenAlex indexes 482 publications with 22,700 citations (h-index 70); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Cardiovascular Disease profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
505 Parnassus Ave Fl 3
San Francisco, CA 94143
Telephone
410-502-7974Provider last certified this registry record 5 Oct 2021.
Clinical trials
- Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy
Sponsor: University of California, San Francisco
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20255 payments
- E.R. Squibb & Sons, L.L.C.Program year20241 payment
- E.R. Squibb & Sons, L.L.C.Program year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
86%Cardiac Myosin Inhibitor43%Camzyos100%Part D≥28 patientsBeta blocker17.3%Metoprolol Succinate76%Carvedilol24%Part D<11 patients+ 4 more classes in this area
Blood & clotting
10.3%Factor Xa inhibitor10.3%Eliquis100%Part D<11 patientsMetabolism & gastrointestinal
3.7%SGLT2 inhibitor3.7%Jardiance100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2025 per NIH RePORTER. The latest:
- Exercise Intolerance in Non Obstructive Hypertrophic Cardiomyopathy
University of California, San Francisco
FY2025$807,495R01HL157238 - Exercise Intolerance in Non Obstructive Hypertrophic Cardiomyopathy
University of California, San Francisco
FY2024$791,347R01HL157238 - Exercise Intolerance in Non Obstructive Hypertrophic Cardiomyopathy
University of California, San Francisco
FY2023$807,497R01HL157238
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
New England Journal of Medicine
2024 - Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology
2023 - Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
European Heart Journal
2023 - Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy: An Update from the American Society of Echocardiography, in Collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography
Journal of the American Society of Echocardiography
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Alan J. Korman
Bristol-Myers Squibb
Ray Hershberger, MD
Bristol-Myers Squibb
Elizabeth M. Johnson
Bristol-Myers Squibb
Fabio Petrocca
Bristol-Myers Squibb
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”